

Asia Pacific Neutropenia Treatment Market By Distribution channel (Retail pharmacies, Hospital pharmacies and Online pharmacies), By Treatment (Colony-stimulating factor, Antibiotics, Antifungals and Antivirals), By Country, Industry Analysis and Forecast, 2020 - 2026

<https://marketpublishers.com/r/A1FFD1918F50EN.html>

Date: June 2020

Pages: 69

Price: US\$ 1,500.00 (Single User License)

ID: A1FFD1918F50EN

Abstracts

The Asia Pacific Neutropenia Treatment Market would witness market growth of 7.6% CAGR during the forecast period (2020-2026).

Neutropenia itself has no specific symptoms but is usually treated with a fever or infection. Often, persistent infection is also what leads doctors to test blood cell counts to identify blood cell cancers such as leukemia. Severe infections can develop quickly when a patient is neutropenic and become overwhelming within minutes to hours. Fortunately, since doctors expect potential changes in immune responses during multiple cancer treatments, they pay careful attention to variations in blood counts to avoid these events.

Cytotoxic chemotherapy can cause severe and often prolonged neutropenia, which can lead to Retailization for fever care or possibly fatal infection. While deep sustained neutropenia is more likely to occur in the pre-engraft process of hematopoietic cell transplantation and in patients undergoing acute leukemia induction therapy, chemotherapy-related neutropenia that also occurs in patients undergoing standard-dose chemotherapy for certain neoplasms. To eliminate infectious risks, recombinant human granulocyte stimulating factor (G-CSF; filgrastim and pegylated filgrastim) and granulocyte-macrophage stimulating factor (GM-CSF; sargramostim) have been used to decrease the length and degree of neutropenia.

A rise in the prevalence of leukemia, an increase in R&D activities and the production of new drugs, and a paradigm change from branded drugs to biosimilars in cancer-friendly

treatment, are transforming the global neutropenia treatment industry. Nevertheless, high costs for the diagnosis of neutropenia and stringent rules for the clearance of products hinder the growth of the market. On the contrary, the robust neutropenia drug pipeline will open up new opportunities for market players over the coming years.

Based on Distribution channel, the market is segmented into Retail pharmacies, Hospital pharmacies and Online pharmacies. Based on Treatment, the market is segmented into Colony-stimulating factor, Antibiotics, Antifungals and Antivirals. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., BeyondSpring, Inc., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd. (Kirin Company), Mylan N.V., Cellerant Therapeutics, Inc., and Partner Therapeutics, Inc.

Scope of the Study

Market Segmentation:

By Distribution Channel

Retail pharmacies

Hospital pharmacies and

Online pharmacies

By Treatment

Colony-stimulating factor

Antibiotics

Antifungals and

Antivirals

By Country

China

Japan

India

South Korea

Singapore

Malaysia

Rest of Asia Pacific

Companies Profiled

Amgen, Inc.

Novartis AG

Pfizer, Inc.

Teva Pharmaceuticals Industries Ltd.

BeyondSpring, Inc.

Spectrum Pharmaceuticals, Inc.

Kyowa Kirin Co., Ltd. (Kirin Company)

Mylan N.V.

Cellerant Therapeutics, Inc.

Partner Therapeutics, Inc.

Unique Offerings from KBV Research

Exhaustive coverage

Highest number of market tables and figures

Subscription based model available

Guaranteed best price

Assured post sales research support with 10% customization free

Contents

CHAPTER 1. MARKET SCOPE & METHODOLOGY

- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
 - 1.4.1 Asia Pacific Neutropenia Treatment Market, by Distribution Channel
 - 1.4.2 Asia Pacific Neutropenia Treatment Market, by Treatment
 - 1.4.3 Asia Pacific Neutropenia Treatment Market, by Country
- 1.5 Methodology for the research

CHAPTER 2. MARKET OVERVIEW

- 2.1 Introduction
 - 2.1.1 Overview
 - 2.1.2 Market Composition and Scenario
- 2.2 Key Factors Impacting the Market
 - 2.2.1 Market Drivers
 - 2.2.2 Market Restraints

CHAPTER 3. ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL

- 3.1 Asia Pacific Retail pharmacies Market by Country
- 3.2 Asia Pacific Hospital pharmacies Market by Country
- 3.3 Asia Pacific Online pharmacies Market by Country

CHAPTER 4. ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY TREATMENT

- 4.1 Asia Pacific Colony-stimulating factor Market by Country
- 4.2 Asia Pacific Antibiotics Market by Country
- 4.3 Asia Pacific Antifungals Market by Country
- 4.4 Asia Pacific Antivirals Market by Country

CHAPTER 5. ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY COUNTRY

- 5.1 China Neutropenia Treatment Market
 - 5.1.1 China Neutropenia Treatment Market by Distribution channel
 - 5.1.2 China Neutropenia Treatment Market by Treatment
- 5.2 Japan Neutropenia Treatment Market
 - 5.2.1 Japan Neutropenia Treatment Market by Distribution channel
 - 5.2.2 Japan Neutropenia Treatment Market by Treatment
- 5.3 India Neutropenia Treatment Market
 - 5.3.1 India Neutropenia Treatment Market by Distribution channel
 - 5.3.2 India Neutropenia Treatment Market by Treatment
- 5.4 South Korea Neutropenia Treatment Market
 - 5.4.1 South Korea Neutropenia Treatment Market by Distribution channel
 - 5.4.2 South Korea Neutropenia Treatment Market by Treatment
- 5.5 Singapore Neutropenia Treatment Market
 - 5.5.1 Singapore Neutropenia Treatment Market by Distribution channel
 - 5.5.2 Singapore Neutropenia Treatment Market by Treatment
- 5.6 Malaysia Neutropenia Treatment Market
 - 5.6.1 Malaysia Neutropenia Treatment Market by Distribution channel
 - 5.6.2 Malaysia Neutropenia Treatment Market by Treatment
- 5.7 Rest of Asia Pacific Neutropenia Treatment Market
 - 5.7.1 Rest of Asia Pacific Neutropenia Treatment Market by Distribution channel
 - 5.7.2 Rest of Asia Pacific Neutropenia Treatment Market by Treatment

CHAPTER 6. COMPANY PROFILES

- 6.1 Amgen, Inc.
 - 6.1.1 Company Overview
 - 6.1.2 Financial Analysis
 - 6.1.3 Research & Development Expense
- 6.2 Novartis AG
 - 6.2.1 Company Overview
 - 6.2.2 Financial Analysis
 - 6.2.3 Segmental and Regional Analysis
 - 6.2.4 Recent strategies and developments:
 - 6.2.4.1 Approvals:
- 6.3 Pfizer, Inc.
 - 6.3.1 Company Overview
 - 6.3.2 Financial Analysis
 - 6.3.3 Segmental and Regional Analysis
 - 6.3.4 Recent strategies and developments:

- 6.3.4.1 Approvals:
- 6.3.4.2 Acquisition and Mergers:
- 6.4 Teva Pharmaceutical Industries Ltd.
 - 6.4.1 Company Overview
 - 6.4.2 Financial Analysis
 - 6.4.3 Regional Analysis
 - 6.4.4 Research & Development Expenses
 - 6.4.5 Recent strategies and developments:
 - 6.4.5.1 Partnerships, Collaborations, and Agreements:
- 6.5 BeyondSpring, Inc.
 - 6.5.1 Company Overview
- 6.6 Spectrum Pharmaceuticals, Inc.
 - 6.6.1 Company Overview
 - 6.6.2 Financial Analysis
 - 6.6.3 Research & Development Expenses
- 6.7 Kyowa Kirin Co., Ltd. (Kirin Company)
 - 6.7.1 Company Overview
 - 6.7.2 Financial Analysis
 - 6.7.3 Regional Analysis
 - 6.7.4 Research & Development Expense
- 6.8 Mylan N.V.
 - 6.8.1 Company Overview
 - 6.8.2 Financial Analysis
 - 6.8.3 Regional Analysis
 - 6.8.4 Research & Development Expense
 - 6.8.5 Recent strategies and developments:
 - 6.8.5.1 Partnerships, Collaborations, and Agreements:
- 6.9 Cellerant Therapeutics, Inc.
 - 6.9.1 Company Overview
 - 6.9.2 Recent strategies and developments:
 - 6.9.2.1 Approvals:
- 6.1 Partner Therapeutics, Inc.
 - 6.10.1 Company overview
 - 6.10.2 Recent strategies and developments:
 - 6.10.2.1 Partnerships, Collaborations, and Agreements:
 - 6.10.2.2 Approvals:

List Of Tables

LIST OF TABLES

TABLE 1 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION

TABLE 2 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION

TABLE 3 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION

TABLE 4 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION

TABLE 5 ASIA PACIFIC RETAIL PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 6 ASIA PACIFIC RETAIL PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 7 ASIA PACIFIC HOSPITAL PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 8 ASIA PACIFIC HOSPITAL PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 9 ASIA PACIFIC ONLINE PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 10 ASIA PACIFIC ONLINE PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 11 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION

TABLE 12 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION

TABLE 13 ASIA PACIFIC COLONY-STIMULATING FACTOR MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 14 ASIA PACIFIC COLONY-STIMULATING FACTOR MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 15 ASIA PACIFIC ANTIBIOTICS MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 16 ASIA PACIFIC ANTIBIOTICS MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 17 ASIA PACIFIC ANTIFUNGALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 18 ASIA PACIFIC ANTIFUNGALS MARKET BY COUNTRY, 2020 - 2026, USD

MILLION

TABLE 19 ASIA PACIFIC ANTIVIRALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 20 ASIA PACIFIC ANTIVIRALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 21 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 22 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 23 CHINA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION

TABLE 24 CHINA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION

TABLE 25 CHINA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION

TABLE 26 CHINA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION

TABLE 27 CHINA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION

TABLE 28 CHINA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION

TABLE 29 JAPAN NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION

TABLE 30 JAPAN NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION

TABLE 31 JAPAN NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION

TABLE 32 JAPAN NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION

TABLE 33 JAPAN NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION

TABLE 34 JAPAN NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION

TABLE 35 INDIA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION

TABLE 36 INDIA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION

TABLE 37 INDIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION

TABLE 38 INDIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION

TABLE 39 INDIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION

TABLE 40 INDIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION

TABLE 41 SOUTH KOREA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION

TABLE 42 SOUTH KOREA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION

TABLE 43 SOUTH KOREA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION

TABLE 44 SOUTH KOREA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION

TABLE 45 SOUTH KOREA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION

TABLE 46 SOUTH KOREA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION

TABLE 47 SINGAPORE NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION

TABLE 48 SINGAPORE NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION

TABLE 49 SINGAPORE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION

TABLE 50 SINGAPORE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION

TABLE 51 SINGAPORE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION

TABLE 52 SINGAPORE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION

TABLE 53 MALAYSIA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION

TABLE 54 MALAYSIA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION

TABLE 55 MALAYSIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION

TABLE 56 MALAYSIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION

TABLE 57 MALAYSIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION

TABLE 58 MALAYSIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020

- 2026, USD MILLION

TABLE 59 REST OF ASIA PACIFIC NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION

TABLE 60 REST OF ASIA PACIFIC NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION

TABLE 61 REST OF ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION

TABLE 62 REST OF ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION

TABLE 63 REST OF ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION

TABLE 64 REST OF ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION

TABLE 65 KEY INFORMATION – AMGEN, INC.

TABLE 66 KEY INFORMATION – NOVARTIS AG

TABLE 67 KEY INFORMATION – PFIZER, INC.

TABLE 68 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.

TABLE 69 KEY INFORMATION – BEYONDSRING, INC.

TABLE 70 KEY INFORMATION – SPECTRUM PHARMACEUTICALS, INC.

TABLE 71 KEY INFORMATION – KYOWA KIRIN CO., LTD.

TABLE 72 KEY INFORMATION – MYLAN N.V.

TABLE 73 KEY INFORMATION – CELLERANT THERAPEUTICS, INC.

TABLE 74 KEY INFORMATION – PARTNER THERAPEUTICS, INC.

List Of Figures

LIST OF FIGURES

FIG 1 METHODOLOGY FOR THE RESEARCH

I would like to order

Product name: Asia Pacific Neutropenia Treatment Market By Distribution channel (Retail pharmacies, Hospital pharmacies and Online pharmacies), By Treatment (Colony-stimulating factor, Antibiotics, Antifungals and Antivirals), By Country, Industry Analysis and Forecast, 2020 - 2026

Product link: <https://marketpublishers.com/r/A1FFD1918F50EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A1FFD1918F50EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970